Dr. Sonpavde on Immunotherapy Plus Chemotherapy in Bladder Cancer

Guru Sonpavde, MD
Published: Wednesday, Apr 04, 2018



Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy plus chemotherapy in bladder cancer.

There are many ongoing trials investigating checkpoint inhibitors in the first-line setting of advanced bladder cancer. In the cisplatin-ineligible space, atezolizumab (Tecentriq) and pembrolizumab (Keytruda) are approved as single agents.

One approach is combining these checkpoint inhibitors with platinum-based chemotherapy in the first-line setting for patients who are both cisplatin-eligible and cisplatin-ineligible. Another approach is combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors. Ongoing trials are investigating these combinations.


Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy plus chemotherapy in bladder cancer.

There are many ongoing trials investigating checkpoint inhibitors in the first-line setting of advanced bladder cancer. In the cisplatin-ineligible space, atezolizumab (Tecentriq) and pembrolizumab (Keytruda) are approved as single agents.

One approach is combining these checkpoint inhibitors with platinum-based chemotherapy in the first-line setting for patients who are both cisplatin-eligible and cisplatin-ineligible. Another approach is combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors. Ongoing trials are investigating these combinations.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x